|
1
|
Stewart BW and Wild CP: World Cancer
Report 2014. International Agency for Research on Cancer; WHO,
Lyon: 2015
|
|
2
|
Hryniewicz-Jankowska A, Augoff K,
Biernatowska A, Podkalicka J and Sikorski AF: Membrane rafts as a
novel target in cancer therapy. Biochim Biophys Acta. 1845:155–165.
2014.PubMed/NCBI
|
|
3
|
Al Saleh S, Sharaf LH and Luqmani YA:
Signalling pathways involved in endocrine resistance in breast
cancer and associations with epithelial to mesenchymal transition
(Review). Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI
|
|
4
|
Chuthapisith S, Eremin J, El-Sheemey M and
Eremin O: Breast cancer chemoresistance: Emerging importance of
cancer stem cells. Surg Oncol. 19:27–32. 2010. View Article : Google Scholar
|
|
5
|
Malenfant SJ, Eckmann KR and Barnett CM:
Pertuzumab: A new targeted therapy for HER2-positive metastatic
breast cancer. Pharmacotherapy. 34:60–71. 2014. View Article : Google Scholar
|
|
6
|
Piccart M: Circumventing de novo and
acquired resistance to trastuzumab: New hope for the care of
ErbB2-positive breast cancer. Clin Breast Cancer. 8(Suppl 3):
S100–S113. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
O'Driscoll L and Clynes M: Biomarkers and
multiple drug resistance in breast cancer. Curr Cancer Drug
Targets. 6:365–384. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gupta PB, Onder TT, Jiang G, Tao K,
Kuperwasser C, Weinberg RA and Lander ES: Identification of
selective inhibitors of cancer stem cells by high-throughput
screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arafat K, Iratni R, Takahashi T, Parekh K,
Al Dhaheri Y, Adrian TE and Attoub S: Inhibitory effects of
salinomycin on cell survival, colony growth, migration, and
invasion of human non-small cell lung cancer A549 and LNM35:
Involvement of NAG-1. PLoS One. 8:e669312013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Al Dhaheri Y, Attoub S, Arafat K, Abuqamar
S, Eid A, Al Faresi N and Iratni R: Salinomycin induces apoptosis
and senescence in breast cancer: Upregulation of p21,
downregulation of survivin and histone H3 and H4 hyperacetylation.
Biochim Biophys Acta. 1830:3121–3135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Koo KH, Kim H, Bae YK, Kim K, Park BK, Lee
CH and Kim YN: Salinomycin induces cell death via inactivation of
Stat3 and downregulation of Skp2. Cell Death Dis. 4:e6932013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li T, Su L, Zhong N, Hao X, Zhong D,
Singhal S and Liu X: Salinomycin induces cell death with autophagy
through activation of endoplasmic reticulum stress in human cancer
cells. Autophagy. 9:1057–1068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ketola K, Hilvo M, Hyötyläinen T, Vuoristo
A, Ruskeepää AL, Orešič M, Kallioniemi O and Iljin K: Salinomycin
inhibits prostate cancer growth and migration via induction of
oxidative stress. Br J Cancer. 106:99–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schenk M, Aykut B, Teske C, Giese NA,
Weitz J and Welsch T: Salinomycin inhibits growth of pancreatic
cancer and cancer cell migration by disruption of actin stress
fiber integrity. Cancer Lett. 358:161–169. 2015. View Article : Google Scholar
|
|
16
|
Kopp F, Hermawan A, Oak PS, Herrmann A,
Wagner E and Roidl A: Salinomycin treatment reduces metastatic
tumor burden by hampering cancer cell migration. Mol Cancer.
13:162014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fuchs D, Daniel V, Sadeghi M, Opelz G and
Naujokat C: Salinomycin overcomes ABC transporter-mediated
multidrug and apoptosis resistance in human leukemia stem cell-like
KG-1a cells. Biochem Biophys Res Commun. 394:1098–1104. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fuchs D, Heinold A, Opelz G, Daniel V and
Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis
resistance in human cancer cells. Biochem Biophys Res Commun.
390:743–749. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim JH, Chae M, Kim WK, Kim YJ, Kang HS,
Kim HS and Yoon S: Salinomycin sensitizes cancer cells to the
effects of doxorubicin and etoposide treatment by increasing DNA
damage and reducing p21 protein. Br J Pharmacol. 162:773–784. 2011.
View Article : Google Scholar :
|
|
20
|
Liffers ST, Tilkorn DJ, Stricker I, Junge
CG, Al-Benna S, Vogt M, Verdoodt B, Steinau HU, Tannapfel A,
Tischoff I, et al: Salinomycin increases chemosensitivity to the
effects of doxorubicin in soft tissue sarcomas. BMC Cancer.
13:4902013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou J, Li P, Xue X, He S, Kuang Y, Zhao
H, Chen S, Zhi Q and Guo X: Salinomycin induces apoptosis in
cisplatin-resistant colorectal cancer cells by accumulation of
reactive oxygen species. Toxicol Lett. 222:139–145. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang B, Wang X, Cai F, Chen W, Loesch U
and Zhong XY: Antitumor properties of salinomycin on
cisplatin-resistant human ovarian cancer cells in vitro and in
vivo: Involvement of p38 MAPK activation. Oncol Rep. 29:1371–1378.
2013.PubMed/NCBI
|
|
23
|
Calzolari A, Saulle E, De Angelis ML,
Pasquini L, Boe A, Pelacchi F, Ricci-Vitiani L, Baiocchi M and
Testa U: Salinomycin potentiates the cytotoxic effects of TRAIL on
glioblastoma cell lines. PLoS One. 9:e944382014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp
UR, Ullrich A, Wagner E, Knyazev P and Roidl A: Combinatorial
treatment of mammospheres with trastuzumab and salinomycin
efficiently targets HER2-positive cancer cells and cancer stem
cells. Int J Cancer. 131:2808–2819. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim KY, Kim SH, Yu SN, Park SK, Choi HD,
Yu HS, Ji JH, Seo YK and Ahn SC: Salinomycin enhances
doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR
human breast cancer cells via decreased efflux of doxorubicin. Mol
Med Rep. 12:1898–1904. 2015.PubMed/NCBI
|
|
26
|
Kopp F, Oak PS, Wagner E and Roidl A:
miR-200c sensitizes breast cancer cells to doxorubicin treatment by
decreasing TrkB and Bmi1 expression. PLoS One. 7:e504692012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kopp F, Hermawan A, Oak PS, Ulaganathan
VK, Herrmann A, Elnikhely N, Thakur C, Xiao Z, Knyazev P, Ataseven
B, et al: Sequential salinomycin treatment results in resistance
formation through clonal selection of epithelial-like tumor cells.
Transl Oncol. 7:702–711. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dönmez Y, Akhmetova L, İşeri OD, Kars MD
and Gündüz U: Effect of MDR modulators verapamil and promethazine
on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant
MCF-7 cells. Cancer Chemother Pharmacol. 67:823–828. 2011.
View Article : Google Scholar
|
|
29
|
Latorre E, Tebaldi T, Viero G, Spartà AM,
Quattrone A and Provenzani A: Downregulation of HuR as a new
mechanism of doxorubicin resistance in breast cancer cells. Mol
Cancer. 11:132012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lin ST, Chou HC, Chang SJ, Chen YW, Lyu
PC, Wang WC, Chang MD and Chan HL: Proteomic analysis of proteins
responsible for the development of doxorubicin resistance in human
uterine cancer cells. J Proteomics. 75:5822–5847. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qinghong S, Shen G, Lina S, Yueming Z,
Xiaoou L, Jianlin W, Chengyan H, Hongjun L and Haifeng Z:
Comparative proteomics analysis of differential proteins in respond
to doxorubicin resistance in myelogenous leukemia cell lines.
Proteome Sci. 13:12015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou Y, Liang C, Xue F, Chen W, Zhi X,
Feng X, Bai X and Liang T: Salinomycin decreases doxorubicin
resistance in hepatocellular carcinoma cells by inhibiting the
β-catenin/TCF complex association via FOXO3a activation.
Oncotarget. 6:10350–10365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cahill DP, Kinzler KW, Vogelstein B and
Lengauer C: Genetic instability and Darwinian selection in tumours.
Trends Cell Biol. 9:M57–M60. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Israeli D, Ziaei S, Gonin P and Garcia L:
A proposal for the physiological significance of mdr1 and
Bcrp1/Abcg2 gene expression in normal tissue regeneration and after
cancer therapy. J Theor Biol. 232:41–45. 2005. View Article : Google Scholar
|
|
35
|
Katayama K, Yoshioka S, Tsukahara S,
Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated
protein kinase pathway results in the down-regulation of
P-glycoprotein. Mol Cancer Ther. 6:2092–2102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou S, Schuetz JD, Bunting KD, Colapietro
AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M,
Nakauchi H, et al: The ABC transporter Bcrp1/ABCG2 is expressed in
a wide variety of stem cells and is a molecular determinant of the
side-population phenotype. Nat Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Doyle L and Ross DD: Multidrug resistance
mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 22:7340–7358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xiang W, Gao A, Liang H, Li C, Gao J, Wang
Q, Shuang B, Zhang J, Yan Y and Wang X: Reversal of
P-glycoprotein-mediated multidrug resistance in vitro by milbemycin
compounds in adriamycin-resistant human breast carcinoma
(MCF-7/adr) cells. Toxicol In Vitro. 24:1474–1481. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hoffmann EK and Lambert IH: Ion channels
and transporters in the development of drug resistance in cancer
cells. Philos Trans R Soc Lond B Biol Sci. 369:201301092014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Drori S, Eytan GD and Assaraf YG:
Potentiation of anticancer-drug cytotoxicity by
multidrug-resistance chemosensitizers involves alterations in
membrane fluidity leading to increased membrane permeability. Eur J
Biochem. 228:1020–1029. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bissinger R, Malik A, Jilani K and Lang F:
Triggering of erythrocyte cell membrane scrambling by salinomycin.
Basic Clin Pharmacol Toxicol. 115:396–402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mitani M, Yamanishi T, Miyazaki Y and
Otake N: Salinomycin effects on mitochondrial ion translocation and
respiration. Antimicrob Agents Chemother. 9:655–660. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matsumori N, Morooka A and Murata M:
Conformation and location of membrane-bound salinomycin-sodium
complex deduced from NMR in isotropic bicelles. J Am Chem Soc.
129:14989–14995. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Boehmerle W and Endres M: Salinomycin
induces calpain and cytochrome c-mediated neuronal cell death. Cell
Death Dis. 2:e1682011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Moitra K, Lou H and Dean M: Multidrug
efflux pumps and cancer stem cells: Insights into multidrug
resistance and therapeutic development. Clin Pharmacol Ther.
89:491–502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bunting KD: ABC transporters as phenotypic
markers and functional regulators of stem cells. Stem Cells.
20:11–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yusa K and Tsuruo T: Reversal mechanism of
multidrug resistance by verapamil: Direct binding of verapamil to
P-glycoprotein on specific sites and transport of verapamil outward
across the plasma membrane of K562/ADM cells. Cancer Res.
49:5002–5006. 1989.PubMed/NCBI
|
|
48
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: Molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
